DNA-encoded Library Technology for Drug Discovery. Este artículo no está disponible.
Idioma: inglés
Editorial: Royal Society of Chemistry, GB, 2025
- Tapa dura
- Nuevo

Librería: Rarewaves.com USA, London, London, Reino UnidoRarewaves.com USA
Vendedor de IberLibro desde 11 de junio de 2025
Condición: Nuevo
EUR 262,29
Descripción del artículo del vendedor
DNA-encoded libraries have numerous advantages over traditional screening methods, including easy identification of compounds and the large quantity of compounds that can be screened simultaneously.This book provides a comprehensive guide to the implementation of DNA-encoded library technology (DELT) in drug discovery for screening and hit validation, illustrated with successful case studies.A valuable resource for researchers in drug discovery, this book is complete with successful case studies to illustrate the best practice in implementation and operation of DELT.
N° de ref. del artículo LU-9781788014878
- Título
- DNA-encoded Library Technology for Drug Discovery
- Autor
- Casey J Krusemark
- Editorial
- Royal Society of Chemistry, GB
- Año de publicación
- 2025
- Estado
- New
- Encuadernación
- Hardback
- Idioma
- inglés
- ISBN 10
- 1788014871
- ISBN 13
- 9781788014878
- Peso del artículo
- 420 gramos
DNA-encoded libraries have numerous advantages over traditional screening methods, including easy identification of compounds and the large quantity of compounds that can be screened simultaneously.
This book provides a comprehensive guide to the implementation of DNA-encoded library technology (DELT) in drug discovery for screening and hit validation, illustrated with successful case studies.
A valuable resource for researchers in drug discovery, this book is complete with successful case studies to illustrate the best practice in implementation and operation of DELT.
“Sinopsis” puede pertenecer a otra edición de este título.
Acerca del autor
Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.
“Acerca de” puede pertenecer a otra edición de este título.